As a result, the company will be extending the dose escalation portion of the study longer than previously communicated.
Mary Tagliaferri, Bionovo’s president and chief medical officer, said: “As a result of this positive news, we will continue the dose escalation, so long as we continue to see favorable tolerability and safety, after which we will transition to the full Phase II study component.”